Search
Mercaptopurine
go.drugbank.com/drugs/DB01033ApprovedInvestigationalIt interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Categories: Drugs for Obstructive Airway DiseasesRilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune … Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies.
Sibeprenlimab
go.drugbank.com/drugs/DB18919ApprovedInvestigational[L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … [A274853, A274858] Sibeprenlimab is a humanized immunoglobulin G2 (IgG2) monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells.
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187547] The drug [MRTX849] is also currently being developed and has the same target. … [A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.
Xenon-133
go.drugbank.com/drugs/DB09315ApprovedXenon-133 is an inhaled radionuclide used for lung imaging, imaging blood flow in the brain, and to assess pulmonary function.
Chloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approved[A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine]. … Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria.
Categories: Experimental Unapproved Treatments for COVID-19Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigational[A20343] Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute … Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalMilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment … Moreover, recent research has shown that the levorotatory enantiomer of milnacipran, levomilnacipran, may have the capacity to inhibit the activity of beta-site amyloid precursor protein cleaving enzyme
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAncestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawnAncestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal
Phenyltoloxamine
go.drugbank.com/drugs/DB11160ApprovedPhenyltoloxamine citrate is the more common salt form that acts as an active ingredient in pharmaceutical products and promotes hay fever relief via reversing the effects of histamine. … Although phenyltoloxamine's ability to potentiate the effects of analgesics may be explained in part by its chemical nature as a first-generation H1 antihistamine that is capable of crossing the blood-brain